For Postherpetic Neuralgia, Current and Emerging Therapies Have No Significant Advantage Over Pfizer's Lyrica on the Attribute

For Postherpetic Neuralgia, Current and Emerging Therapies Have No Significant
  Advantage Over Pfizer's Lyrica on the Attribute of Reducing Pain Intensity

Greater Reduction in Pain Intensity is One of the Greatest Unmet Needs in
Postherpetic Neuralgia, According to a New Report from Decision Resources

PR Newswire

BURLINGTON, Mass., April 9, 2013

BURLINGTON, Mass., April 9, 2013 /PRNewswire/ -- Decision Resources, one of
the world's leading research and advisory firms for pharmaceutical and
healthcare issues, finds that surveyed U.S. and European neurologists agree
that reduction in pain intensity is one of the attributes that most influences
their decisions regarding prescribing in postherpetic neuralgia (PHN).
Furthermore, according to insights from surveyed neurologists and managed care
organization (MCO) pharmacy directors, greater reduction in pain intensity is
one of the most important unmet needs in PHN. Nevertheless, clinical data and
the opinions of interviewed thought leaders indicate that current and emerging
therapies have no significant advantage over patient-share leader pregabalin
(Pfizer's Lyrica) on this attribute.

(Logo: )

The DecisionBase 2013 report entitled Will Delivery Advantages Translate into
Payer and Physician Receptivity? finds that surveyed U.S. neurologists
indicate that they would prescribe pregabalin controlled-release (CR) to 40
percent of their PHN patients. Decision Resources forecasts that pregabalin CR
will earn a more-modest patient share in the U.S. PHN market by 2021 of
slightly less than 20 percent, driven largely by its once-daily delivery
advantage but offset by the forthcoming generic entry of immediate-release
(IR) pregabalin.

"Pregabalin CR's once-daily dosing will not prove to be enough of a compelling
advantage to physicians and payers once pregabalin IR is generically
available," said Decision Resources Analyst Andrea Buurma. "This, in addition
to a lack of clear efficacy and/or tolerability benefit over the IR
formulation to date will ultimately constrain pregabalin CR's uptake." 

The report also finds that surveyed MCO pharmacy directors receptive to new
PHN therapies that offer substantial improvements in patient responder rate 
over currently available therapies. While some emerging therapies hold
promise, Decision Resources does not expect any will match the clinical
improvement over current therapies that surveyed U.S. payers indicated would
be necessary for widespread inclusion on MCO formularies.

About Decision Resources

Decision Resources ( is a world leader in market
research publications, advisory services and consulting designed to help
clients shape strategy, allocate resources and master their chosen markets.
Decision Resources is a Decision Resources Group company.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers
best-in-class, high-value information and insights on important sectors of the
healthcare industry. Clients rely on this analysis and data to make informed
decisions. Please visit Decision Resources Group at

All company, brand, or product names contained in this document may be
trademarks or registered trademarks of their respective holders.

SOURCE Decision Resources

Contact: Decision Resources, Christopher Comfort, 781-993-2597,
Press spacebar to pause and continue. Press esc to stop.